Terumo BCT receives FDA clearance to collect platelets on Trima Accel system

Published on April 10, 2013 at 7:49 AM · 1 Comment

Terumo BCT has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to collect platelets on the Trima Accel system for storage in Isoplate platelet additive solution (PAS), which replaces a portion of the plasma in blood products. Blood centers in the United States can now collect platelets on the Trima Accel system in 65 percent less plasma volume and store platelets in Isoplate for up to five days, which reduces the single-donor plasma volume in the transfused platelet product.

“This is a great achievement. Our technology offers many benefits. With the inclusion of the PAS product offering on the Trima Accel system, we are able to help our customers enhance their productivity while delivering beneficial care to patients.”

KEY FACTS:

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
  1. David Gremillion David Gremillion United States says:

    I wonder if the AABB will consider apheresis platelets manufuctured using this technology a TRALI low risk product similar to whole blood derived platelet concentrates?

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post